Year in Review

Matching-adjusted indirect comparison of liso-cel to axi-cel utilizing data from the TRANSFORM and ZUMA-7 studies revealed lower odds of key CAR-T‒associated adverse events with liso-cel. Read More ›

Phase 1 results of YTB323 in patients with R/R DLBCL demonstrate durable efficacy with a favorable safety profile, as well as identify the recommended phase 2/3 dose. Read More ›

Data from the CIBMTR registry revealed that advanced age does not impact mortality associated with CAR-T therapy, and that CAR-T therapy is feasible in older adults. Read More ›

Two distinct inflammatory clusters were identified and found to be tightly linked to response and survival of patients with LBCL receiving CAR-T therapy, with validation utilizing an independent cohort. Read More ›

Mechanisms of acquired resistance to anti–PD-(L)1 therapy in patients with advanced NSCLC are heterogeneous and require novel therapeutic strategies to be surmounted. Read More ›

Analysis of circulating tumor DNA can identify patients at high risk of early disease progression who could benefit from combining immune checkpoint inhibitors with chemotherapy. Read More ›

A highly multiplexed proteomic assay was developed to guide treatment selection for patients with lung cancer. Read More ›

Implementing a machine learning–based system that integrates radiologic, pathologic, and genomic data to predict response to PD-1 blockade may be able to outperform conventional unimodal approaches. Read More ›

Administering nivolumab in the morning improved progression-free survival and overall survival compared with administration during later times of the day, suggesting that circadian rhythm may affect its efficacy. Read More ›

Transcriptional signatures of COPII vesicle and Golgi targeting were identified as potential novel response biomarkers to vidutolimod, a first-in-class CpG-A TLR9 agonist, in combination anti–PD-L1-targeted therapy. Read More ›

Page 3 of 9